The presence of a heterozygous BRCA2 mutation confers increased lifetime risks for male breast cancer, prostate cancer, pancreatic cancer, melanoma, and central nervous system (CNS) tumors, thus warranting early cancer surveillance strategies and genetic counseling for the patient and at-risk relatives [10]. This evidence concerns the gene BRCA2 and cancer.